Regenerative medicine is one of the areas I’ve worked in — and one where the potential is still enormous. I’ve seen teams make what looks like the best possible decision: Choose the therapy that performs best in trials. The data is clean The efficacy signal is strong.The science is compelling. There’s very little debate.

And for a while, everything looks right. Until about two years later, when a different reality starts to surface. Not in the clinic, but in manufacturing, delivery, and cost.

I remember one situation where the therapy worked exactly as intended. But, the process was too complex to scale, the cost per patient kept climbing, and every incremental improvement made the system more fragile, not less At that point, the problem wasn’t scientific anymore. It was structural. And by then, the path was already set:

platform locked

infrastructure built

capital committed

Reversing course would have meant starting over.

So the team kept going, trying to optimize around a constraint that had already been decided.

That’s the trap - In regenerative medicine, failure is visible early. Success is what quietly locks you in. Because the real decision isn’t just: “Does the therapy work?”

It’s: “Can this ever become something you can actually deliver at scale?”

You don’t discover the constraint when it fails. You discover it when it works.